Literature DB >> 22137775

The European Psychiatric Association (EPA) guidance on suicide treatment and prevention.

D Wasserman1, Z Rihmer, D Rujescu, M Sarchiapone, M Sokolowski, D Titelman, G Zalsman, Z Zemishlany, V Carli.   

Abstract

UNLABELLED: Suicide is a major public health problem in the WHO European Region accounting for over 150,000 deaths per year. SUICIDAL CRISIS: Acute intervention should start immediately in order to keep the patient alive. DIAGNOSIS: An underlying psychiatric disorder is present in up to 90% of people who completed suicide. Comorbidity with depression, anxiety, substance abuse and personality disorders is high. In order to achieve successful prevention of suicidality, adequate diagnostic procedures and appropriate treatment for the underlying disorder are essential. TREATMENT: Existing evidence supports the efficacy of pharmacological treatment and cognitive behavioural therapy (CBT) in preventing suicidal behaviour. Some other psychological treatments are promising, but the supporting evidence is currently insufficient. Studies show that antidepressant treatment decreases the risk for suicidality among depressed patients. However, the risk of suicidal behaviour in depressed patients treated with antidepressants exists during the first 10-14 days of treatment, which requires careful monitoring. Short-term supplementary medication with anxiolytics and hypnotics in the case of anxiety and insomnia is recommended. Treatment with antidepressants of children and adolescents should only be given under supervision of a specialist. Long-term treatment with lithium has been shown to be effective in preventing both suicide and attempted suicide in patients with unipolar and bipolar depression. Treatment with clozapine is effective in reducing suicidal behaviour in patients with schizophrenia. Other atypical antipsychotics are promising but more evidence is required. TREATMENT TEAM: Multidisciplinary treatment teams including psychiatrist and other professionals such as psychologist, social worker, and occupational therapist are always preferable, as integration of pharmacological, psychological and social rehabilitation is recommended especially for patients with chronic suicidality. FAMILY: The suicidal person independently of age should always be motivated to involve family in the treatment. SOCIAL SUPPORT: Psychosocial treatment and support is recommended, as the majority of suicidal patients have problems with relationships, work, school and lack functioning social networks. SAFETY: A secure home, public and hospital environment, without access to suicidal means is a necessary strategy in suicide prevention. Each treatment option, prescription of medication and discharge of the patient from hospital should be carefully evaluated against the involved risks. TRAINING OF PERSONNEL: Training of general practitioners (GPs) is effective in the prevention of suicide. It improves treatment of depression and anxiety, quality of the provided care and attitudes towards suicide. Continuous training including discussions about ethical and legal issues is necessary for psychiatrists and other mental health professionals.
Copyright © 2011 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22137775     DOI: 10.1016/j.eurpsy.2011.06.003

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  61 in total

1.  Laboratory of the Neuropsychology and Cognitive Neurosciences Research Center of Universidad Católica del Maule, Chile.

Authors:  Boris Lucero; Chiara Saracini; María Teresa Muñoz-Quezada; Pablo Mendez-Bustos; Marco Mora
Journal:  Cogn Process       Date:  2018-06-14

Review 2.  Epidemiology, neurobiology and pharmacological interventions related to suicide deaths and suicide attempts in bipolar disorder: Part I of a report of the International Society for Bipolar Disorders Task Force on Suicide in Bipolar Disorder.

Authors:  Ayal Schaffer; Erkki T Isometsä; Leonardo Tondo; Doris H Moreno; Mark Sinyor; Lars Vedel Kessing; Gustavo Turecki; Abraham Weizman; Jean-Michel Azorin; Kyooseob Ha; Catherine Reis; Frederick Cassidy; Tina Goldstein; Zoltán Rihmer; Annette Beautrais; Yuan-Hwa Chou; Nancy Diazgranados; Anthony J Levitt; Carlos A Zarate; Lakshmi Yatham
Journal:  Aust N Z J Psychiatry       Date:  2015-07-16       Impact factor: 5.744

Review 3.  An overview of the neurobiology of suicidal behaviors as one meta-system.

Authors:  M Sokolowski; J Wasserman; D Wasserman
Journal:  Mol Psychiatry       Date:  2014-09-02       Impact factor: 15.992

Review 4.  A review of multidisciplinary clinical practice guidelines in suicide prevention: toward an emerging standard in suicide risk assessment and management, training and practice.

Authors:  Rebecca A Bernert; Melanie A Hom; Laura Weiss Roberts
Journal:  Acad Psychiatry       Date:  2014-08-21

5.  [Time-related aspects of suicides - suicide frequency related to birthday, major holidays, day of the week, season, month of birth and zodiac signs].

Authors:  Eberhard A Deisenhammer; Christoph Stiglbauer; Georg Kemmler
Journal:  Neuropsychiatr       Date:  2018-03-07

Review 6.  Can we really prevent suicide?

Authors:  Maya Schwartz-Lifshitz; Gil Zalsman; Lucas Giner; Maria A Oquendo
Journal:  Curr Psychiatry Rep       Date:  2012-12       Impact factor: 5.285

7.  Characteristics of U.S. suicide decedents in 2005-2010 who had received mental health treatment.

Authors:  Thomas Niederkrotenthaler; Joseph E Logan; Debra L Karch; Alex Crosby
Journal:  Psychiatr Serv       Date:  2014-03-01       Impact factor: 3.084

Review 8.  [Psychopharmaceuticals for treatment of suicidal patients and for suicide prevention].

Authors:  R Haußmann; M Bauer; U Lewitzka; B Müller-Oerlinghausen
Journal:  Nervenarzt       Date:  2016-05       Impact factor: 1.214

9.  Perils of Pragmatic Psychiatry: How We Can Do Better.

Authors:  Maju Mathew Koola; Joseph Sebastian
Journal:  HSOA J Psychiatry Depress Anxiety       Date:  2016-02-23

Review 10.  Behavioural therapy of suicidality.

Authors:  Barbara Schneider
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-08-28       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.